New treatments for diabetic neuropathy: Pathogenetically oriented treatment

Current Diabetes Reports

Volumn 3, Issue 6, 2003, Pages 452-458

  Bierhaus, Angelika ^a   Humpert, Per M ^a   Rudofsky, Gottfried ^a   Wendt, Thoralf ^a   Morcos, Michael ^a   Hamann, Andreas ^a   Nawroth, Peter P ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; ALPHA TOCOPHEROL; ANTIOXIDANT; BENFOTIAMINE; BUTYLCRESOL; GAMMA LINOLENIC ACID; GLUTATHIONE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PLACEBO; PRASTERONE; PROBUCOL; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; PYRROLIDINE DITHIOCARBAMATE; REACTIVE OXYGEN METABOLITE; RUBOXISTAURIN; TAURINE; THIOCTIC ACID; TOSYLLYSYL CHLOROMETHYL KETONE;

APOPTOSIS; CELL DISRUPTION; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIET SUPPLEMENTATION; DISEASE MODEL; ENZYME ACTIVATION; HUMAN; LIPOLYSIS; METHODOLOGY; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; SENSORY NEUROPATHY; VASCULAR DISEASE;

EID: 3142770543     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-003-0007-z     Document Type: Review

References (50)

1. Vinik AI: Diabetic neuropathy: pathogenesis and therapy. Am J Med 1999, 107(2B): 17S-26S.
2. Feldman E: Oxidative stress and diabetic neuropathy: a new understanding of an old problem. J Clin Invest 2003, 111:431-433.
3. Cameron NE, Cotter MA: Oxidative stress and abnormal lipid metabolism in diabetic complications. In Frontiers in Animal Diabetes Research. Chronic Complications in Diabetes. Edited by Sima AAF. Amsterdam: Harwood Academic; 2000:93-130.
4. Romero FJ, Monsalve E, Hermenegildo C, et al.: Oxygen toxicity in the nervous tissue: comparison of the antioxidant defense of rat brain and sciatic nerve. Neurochem Res 1991, 16:157-161.
5. Coppey LJ, Gellett JS, Davidson EP, et al.: Effect of M40403 treatment of diabetic rats on endoneurial blood flow, motor nerve conduction velocity and vascular function of epineurial arterioles of the sciatic nerve. Br J Pharmacol 2001, 134:21-29.
6. Cameron NE, Eaton SE, Cotter MA, Tesfaye S: Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 2001, 44:1973-1988.
7. Packer L, Tritschler HJ, Wessel K: Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Free Radic Biol Med 1997, 22:359-378.
8. Tutuncu NB, Bayraktar M, Varli K: Reversal of defective nerve conduction with vitamin E supplementation in type 2 diabetes: a preliminary study. Diabetes Care 1998, 21:1915-1918.
9. Sadekov RA, Danilov AB, Vein AM: Diabetic polyneuropathy treatment by benfotiamine. Arzneimittelforschung 1999, 49:220-224.
10. Ziegler D, Hanefeld M, Ruhnau KJ, et al.: Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia 1995, 38:1425-1433.
11. Ziegler D, Hanefeld M, Ruhnau KJ, et al.: Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care 1999, 22:1296-1301.
12. Ametov A, Barinov A, Dyck PJ, et al.: The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic Acid: the SYDNEY trial. Diabetes Care 2003, 26:770-776.
13. Collins T, Cybulsky MI: NF-kappaB: pivotal mediator or innocent bystander in atherogenesis? J Clin Invest 2001, 107:255-264.
14. Purves TD, Tomlinson DR: Diminished transcription factor survival signals in dorsal root ganglia in rats with streptozotocin-induced diabetes. Ann N Y Acad Sci 2002, 973:472-476.
15. Cotter A, Cameron N: Effects of nuclear factor kappa B inhibition on neurovascular dysfunction. Diabetes 2003, 52(suppl 1):A192, P825.
16. Bierhaus A, Haslbeck M, Humpert PM, et al.: The role of RAGE mediated NF-kB activation in diabetic neuropathy and its possible role in loss of pain perception. Diabetes 2003, 52(suppl 1): A4, OR18.
17. Okamoto K, Martin DP, Schmelzer JD, et al.: Pro- and anti-inflammatory cytokine gene expression in rat sciatic nerve chronic constriction injury model of neuropathic pain. Exp Neurol 2001, 169:386-391.
18. Machelska H, Cabot PJ, Mousa SA, et al.: Pain control in inflammation governed by selectins. Nat Med 1998, 4:1425-1428.
19. Sakaue G, Shimaoka M, Fukuoka T, et al.: NF-kappa B decoy suppresses cytokine expression and thermal hyperalgesia in a rat neuropathic pain model. Neuroreport 2001, 12:2079-2084.
20. Castagne V, Lefevre K, Clarke PG: Dual role of the NF-kappaB transcription factor in the death of immature neurons. Neuroscience 2001, 108:517-526.
21. Kaltschmidt B, Heinrich M, Kaltschmidt C: Stimulus-dependent activation of NF-kappaB specifies apoptosis or neuroprotection in cerebellar granule cells. Neuromolecular Med 2002, 2:299-309.
22. Vincent AM, Brownlee M, Russell JW: Oxidative stress and programmed cell death in diabetic neuropathy. Ann N Y Acad Sci 2002, 959:368-383.
23. Srinivasan S, Stevens M, Wiley JW: Diabetic peripheral neuropathy: evidence for apoptosis and associated mitochondrial dysfunction. Diabetes 2000, 49:1932-1938.
24. Honma H, Podratz JL, Windebank AJ: Acute glucose deprivation leads to apoptosis in a cell model of acute diabetic neuropathy. J Peripher Nerv Syst 2003, 8:65-74.
25. Bucala R, Tracey KJ, Cerami A: Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991, 87:432-438.
26. Chan NN, Vallance P: Hyperhomocysteinaemia and neuropathy in type 2 diabetes. Diabet Med 2001, 18:1008-1009.
27. Cotter MA, Ekberg K, Wahren J, Cameron NE: Effects of proinsulin C-peptide in experimental diabetic neuropathy: vascular actions and modulation by nitric oxide synthase inhibition. Diabetes 2003, 52:1812-1817.
28. Pierson CR, Zhang W, Sima AA: Proinsulin C-peptide replacement in type 1 diabetic BB/Wor-rats prevents deficits in nerve fiber regeneration. J Neuropathol Exp Neurol 2003, 62:765-779.
29. Hafer-Macko CE, Ivey FM, Gyure KA, et al.: Thrombomodulin deficiency in human diabetic nerve microvasculature. Diabetes 2002, 51:1957-1963.
30. Schratzberger P, Schratzberger G, Silver M, et al.: Favorable effect of VEGF gene transfer on ischemic peripheral neuropathy. Nat Med 2000, 6:405-413.
31. Eaton SE, Harris ND, Ibrahim S, et al.: Increased sural nerve epineurial blood flow in human subjects with painful diabetic neuropathy. Diabetologia 2003, 46:934-939.
32. Cameron NE, Cotter MA, Low PA: Nerve blood flow in early experimental diabetes in rats: relation to conduction deficits. Am J Physiol 1991, 261:E1-E8.
33. Stevens EJ, Carrington AL, Tomlinson DR: Nerve ischaemia in diabetic rats: time-course of development, effect of insulin treatment plus comparison of streptozotocin and BB models. Diabetologia 1994, 37:43-48.
34. Zochodne DW. Diabetic neuropathies: features and mechanisms. Brain Pathol 1999, 9:369-391.
35. Malik RA, Williamson S, Abbott C, et al.: Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet 1998, 352:1978-1981.
36. Toyota T, Hirata Y, Ikeda Y, et al.: Lipo-PGE1, a new lipid-encapsulated preparation of prostaglandin E1: placebo-and prostaglandin E1-controlled multicenter trials in patients with diabetic neuropathy and leg ulcers. Prostaglandins 1993, 46:453-468.
37. Yuen KC, Baker NR, Rayman G: Treatment of chronic painful diabetic neuropathy with isosorbide dinitrate spray: a double-blind placebo-controlled cross-over study. Diabetes Care 2002, 25:1699-1703.
38. Ekberg K, Brismar T, Johansson BL, et al.: Amelioration of sensory nerve dysfunction by C-peptide in patients with type 1 diabetes. Diabetes 2003, 52:536-541.
39. Cotter MA, Cameron NE: Effects of dietary supplementation with arachidonic acid rich oils on nerve conduction and blood flow in streptozotocin-diabetic rats. Prostaglandins Leukot Essent Fatty Acids 1997, 56:337-343.
40. Hounsom L, Horrobin DF, Tritschler H, et al.: A lipoic acid-gamma linolenic acid conjugate is effective against multiple indices of experimental diabetic neuropathy. Diabetologia 1998, 41:839-843.
41. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
42. Oates PJ: Polyol pathway and diabetic peripheral neuropathy. Int Rev Neurobiol 2002, 50:325-392.
43. Sima AAF, Pierson CR: Metabolic alterations in experimental models. in Textbook of Diabetic Neuropathy. Edited by Gries FA, et al. Stuttgart, Germany: Georg Thieme-Verlag; 2003:96-105.
44. Song Z, Fu DT, Chan YS, et al.: Transgenic mice overexpressing aldose reductase in Schwann cells show more severe nerve conduction velocity deficit and oxidative stress under hyperglycemic stress. Mol Cell Neurosci 2003, 23:638-647.
45. Obrosova IG: How does glucose generate oxidative stress in peripheral nerve? Int Rev Neurobiol 2002, 50:3-35.
46. Eichberg J: Protein kinase C changes in diabetes: is the concept relevant to neuropathy? Int Rev Neurobiol 2002, 50:61-82.
47. Wheeler GD: Ruboxistaurin (Eli Lilly). IDrugs 2003, 6:159-163.
48. King RH: The role of glycation in the pathogenesis of diabetic polyneuropathy. Mol Pathol 2001, 54:400-408.
49. Bierhaus A, Schiekofer S, Schwaninger M, et al.: Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 2001, 50:2792-2808.
50. Schmidt AM, Stern DM: RAGE: a new target for the prevention and treatment of the vascular and inflammatory complications of diabetes. Trends Endocrinol Metab 2000, 11:368-375.